Big impact of nanoparticles: analysis of the most cited nanopharmaceuticals and nanonutraceuticals research
Andy Wai Kan Yeung, Eliana B. Souto, Alessandra Durazzo and 6 more
Current Research in Biotechnology · 2020
doi:10.1016/j.crbiot.2020.04.002 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Nanopharmaceuticals and nanonutraceuticals research has been lately receiving a lot of scientific attention. We aimed to identify the top 100 most cited original articles of the scientific area, analyze their research themes, major contributors regarding authors, institutions, countries and journals. The bibliometric data was extracted from the Web of Science electronic database. Data was further processed by a bibliometric software, VOSviewer, to generate bubble maps to visualize the results. Inter-institutional and international collaboration networks were constructed to further understand the cooperation between different study centers. Results revealed that over 60% of the articles were published in the 2000s. As of November 2019, the articles were cited 576–3665 times, with 20.1–261.8 citations per year. The majority of the most prolific institutions were based in the United States. Besides the United States, China, South Korea, Canada and Germany contributed heavily to the 100 articles. Some popular themes included drug delivery, tumor, toxicity/biocompatibility and biodistribution. Regarding composition materials, gold, silver and polymeric nanoparticles were the most commonly used.
Abstract licence: CC BY-NC
References100
- 8.
- 21.
38 more references, whose wording the paper’s licence keeps private.
All 100 referencesCited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.